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Background-—Assessing hospital quality in the performance of carotid endarterectomy (CEA) requires appropriate risk adjustment
across hospitals with varying case mixes. The aim of this study was to develop and validate a prediction model to assess the risk
of in-hospital stroke or death after CEA that could aid in the assessment of hospital quality.
Methods and Results-—Patients from National Cardiovascular Data Registry (NCDR)’s Carotid Artery Revascularization and
Endarterectomy (CARE) Registry undergoing CEA without acute evolving stroke from 2005 to 2013 were included. In-hospital
stroke or death was modeled using hierarchical logistic regression with 20 candidate variables and accounting for hospital-level
clustering. Internal validation was achieved with bootstrapping; model discrimination and calibration were assessed. A total of 213
(1.7%) primary end point events occurred during 12 889 procedures. Independent predictors of stroke or death included age, prior
peripheral artery disease, diabetes mellitus, prior coronary artery disease, having a symptomatic carotid lesion, having a
contralateral carotid occlusion, or having New York Heart Association Class III or IV heart failure. The model was well calibrated and
demonstrated moderate discriminative ability (c-statistic 0.65). The NCDR CEA score was then developed to support simple,
prospective risk quantiﬁcation in the clinical setting.
Conclusions-—The NCDR CEA score, comprising 7 clinical variables, predicts in-hospital stroke or death after CEA. This model can
be used to estimate hospital risk-adjusted outcomes for CEA and to assist with the assessment of hospital quality. (J Am Heart
Assoc. 2014;3:e000728 doi: 10.1161/JAHA.113.000728)
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C
arotid endarterectomy (CEA) reduces stroke risk in both
symptomatic and asymptomatic patients with carotid
atherosclerosis compared with medical therapy.
1–4 While a
number of studies have considered many potential risk
factors for the development of adverse events after CEA, only
a few have offered overall risk assessments for patients
considering CEA.
5–12 These studies have been limited to
reporting experience in Medicare populations,
8 in clinical trial
populations,
7,9 in asymptomatic patients only,
8,11 in a smaller
number of centers in Canada before aggressive lipid-lowering
and antiplatelet therapy was standard,
6 or based on admin-
istrative data sets.
12
The National Cardiovascular Data Registry (NCDR), includ-
ing the Carotid Artery Revascularization and Endarterectomy
(CARE) Registry, provides innovative platforms to assess
hospital quality. Sponsored by the American College of
Cardiology Foundation in conjunction with the Society for
Cardiovascular Angiography and Interventions, Society of
Interventional Radiology, American Academy of Neurology,
American Association of Neurological Surgeons/Congress of
Neurological Surgeons, Society for Vascular Medicine, and
Society of Vascular and Interventional Neurology, the CARE
Registry was designed to create a national surveillance
system to assess prevalence and outcomes of patient
undergoing carotid revascularization. As of November 2013,
130 hospitals participate in the registry.
13 Participating
hospitals receive quarterly reports with information pertaining
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ORIGINAL RESEARCHto number of procedures performed, patient characteristics,
and measures of quality including discharge medication
prescriptions and crude rates of complications such as
in-hospital stroke and death. However, because of differences
in case mix among hospitals, differences in crude adverse
event rates may be a reﬂection of differences in patient
complexity, particularly with respect to clinical features that
strongly inﬂuence outcomes.
While most attempts to assess hospital procedural quality
have relied on administrative claims data,
14 observational
registries that include prospectively collected clinical data
such as the CARE Registry afford the opportunity to create
validated, clinically based prediction models to serve as the
basis for risk adjustment for hospital quality reports. In this
report, we used the CARE Registry to develop and validate a
preprocedural risk model and risk score that will be used to
provide feedback on risk-adjusted outcomes after CEA to
participating hospitals to promote quality improvement.
Methods
The CARE Registry enrolls patients with carotid stenosis who
have undergone revascularization with either CEA or carotid
artery stenting (CAS).
15 Between April 2005 and July 2013,
the registry accrued data from 12 889 CEA procedures
performed at 60 hospitals. Data elements and deﬁnitions are
listed at https://www.ncdr.com/webncdr/care/home/data-
collection. Detailed quality checks are implemented before
incorporation of data into the registry.
16 A waiver of written
informed consent and authorization for this study was granted
by the Chesapeake Research Review Incorporated Institu-
tional Review Board.
To maximize the applicability of the ﬁndings, all except
those undergoing CEA for acute evolving stroke were
included. The primary outcome of interest was the occurrence
of in-hospital stroke or death. Stroke was deﬁned as a new
neurologic deﬁcit persisting for at least 24 hours after the
procedure. Outcomes were abstracted by trained data
collectors.
Statistical Analyses
We examined broad ranges of variables related to sociode-
mographic characteristics, cardiovascular history, and neuro-
logic history based on clinical experience and understanding
of the literature. We conducted bivariate comparisons of
characteristics of patients with or without the outcome of
interest (Table 1) by using v
2 tests for dichotomous variables
and t tests for continuous variables. We then generated a
logistic model for the primary end point conditioned on
clinical variables.
17 Variables were selected using backward
elimination of 20 variables using a criterion of P<0.05 to
remain. Model coefﬁcients were then reﬁt using a hierarchical
generalized linear model accounting for clustering by hospital
(see supplemental online Appendix).
The performance of a prediction model within a sample of
data may overestimate the true performance of the model
within the broader population. The difference between the
“apparent performance” and the true performance is known
as “optimism.”
18 The extent of optimism of prespeciﬁed
models can be estimated for similar patient populations using
internal validation techniques such as bootstrapping. After
ﬁtting the model, we conducted internal validation by reﬁtting
the model in 1000 bootstrap samples with replacement.
Measures of model performance were corrected for opti-
mism, and the ﬁnal model was recalibrated based on a
“shrinkage” factor derived from the calibration slope.
17 To
further assess calibration, we ﬁtted a smoothed line showing
the relationship between predicted and observed risk of in-
hospital stroke or death based on the ﬁnal model.
17 This
method has less variability and less potential bias compared
with traditional split-sample validation and k-fold cross-
validation.
19 To assess variability in risk-adjusted event rates
among hospitals, we estimated the “predicted”-to-expected
ratio of in-hospital stroke or death (or the standardized
adverse event ratio) for each hospital based on its observed
case mix.
20 To support routine clinical use, we developed a
risk score based on a points system with weights based on
the coefﬁcients in the ﬁnal clinical model.
21
Values of P<0.05 (2-tailed) were considered statistically
signiﬁcant. Statistical analyses were performed using SAS 9.2
(SAS Institute) and R.
Results
There were a total of 213 (1.7%) in-hospital stroke or death
events after 12 889 CEA procedures. Stroke occurred in 179
(1.4%) and death occurred in 52 (0.4%) patients. Of the
strokes, 124 (69.2%) were ipsilateral to the revascularized
artery. Bivariate analysis (Table 1) demonstrated that individ-
uals who developed in-hospital stroke or death were older and
were more likely to have peripheral artery disease (PAD),
signiﬁcant coronary artery disease, recent myocardial infarc-
tion, or congestive heart failure. They were also more likely to
have a tracheostomy present or have preexisting laryngeal
nerve palsy. Patients who developed in-hospital stroke or
death were more likely to have had a prior ischemic stroke,
were more likely to be symptomatic from the target lesion, or
were more likely to have a contralateral carotid occlusion.
Multivariable Model
After multivariable regression, 7 variables were retained in the
ﬁnal model (Table 2). These variables included age, PAD,
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HTable 1. Baseline Clinical Characteristics
Characteristic Total
Stroke or
Death No Stroke or Death P Value
(N=12 889) (n=213) (n=12 676)
Age, y 70.810.6 72.910.1 70.810.6 0.004
Age ≥80 y 2459 (19.1%) 55 (25.8%) 2404 (19.0%) 0.012
Male 7603 (59.0%) 116 (54.5%) 7487 (59.1%) 0.175
White 7603 (59.0%) 116 (54.5%) 7487 (59.1%) 0.175
GFR, mL/min per 1.73 m
2 72.430.8 70.826.0 72.430.9 0.477
GFR<30, mL/min per 1.73 m
2 or current dialysis 568 (4.4%) 9 (4.2%) 559 (4.4%) 0.896
Current dialysis 216 (1.7%) 5 (2.3%) 211 (1.7%) 0.411
Tobacco use 9307 (72.2%) 149 (70.0%) 9158 (72.2%) 0.459
Hypertension 11 526 (89.4%) 197 (92.5%) 11 329 (89.4%) 0.143
Dyslipidemia 10 502 (81.5%) 166 (77.9%) 10 336 (81.5%) 0.178
Peripheral artery disease 3979 (30.9%) 85 (39.9%) 3894 (30.7%) 0.004
Diabetes mellitus 4518 (35.1%) 91 (42.7%) 4427 (34.9%) 0.018
Chronic lung disease 2826 (21.9%) 60 (28.2%) 2766 (21.8%) 0.026







Major surgery planned within 8 wk 471 (3.7%) 24 (11.3%) 447 (3.5%) <0.001
Type of major surgery 0.002
Cardiac 305 (65.0%) 22 (95.7%) 283 (63.5%)
Vascular 99 (21.1%) 0 (0.0%) 99 (22.2%)
Other 65 (13.9%) 1 (4.3%) 64 (14.3%)
(N=12 416) (n=189) (n=12 227)
Previous neck radiation 115 (0.9%) 5 (2.3%) 110 (0.9%) 0.042
Previous neck surgery 115 (0.9%) 5 (2.3%) 110 (0.9%) 0.042
Previous laryngeal nerve palsy 0.003
No 12 842 (99.7%) 209 (98.1%) 12 633 (99.7%)
Yes, right 25 (0.2%) 2 (0.9%) 23 (0.2%)
Yes, left 14 (0.1%) 2 (0.9%) 12 (0.1%)
Cardiac history
Ischemic heart disease 5486 (42.6%) 105 (49.3%) 5381 (42.5%) 0.046
Two or more coronary arteries with stenosis ≥70% (LAD, LCx, RCA) 2890 (22.7%) 61 (29.3%) 2829 (22.6%) 0.021
Left main coronary stenosis ≥50% 521 (4.1%) 19 (9.2%) 502 (4.0%) <0.001
MI within 6 wk 181 (1.4%) 10 (4.7%) 171 (1.3%) <0.001
Angina CCS Angina Class III or IV within 6 wk 306 (2.4%) 15 (7.0%) 291 (2.3%) <0.001
History of heart failure 1221 (9.5%) 36 (16.9%) 1185 (9.4%) <0.001
NYHA Class III or IV within 6 wk 306 (2.4%) 15 (7.0%) 291 (2.3%) <0.001
NYHA Class III/IV or LVEF ≤35% 626 (4.9%) 23 (10.8%) 603 (4.8%) <0.001
LVEF assessed preprocedure 6816 (52.9%) 139 (65.3%) 6677 (52.7%) <0.001
LVEF ≤35% 385 (3.0%) 14 (6.6%) 371 (2.9%) 0.002
History of atrial fibrillation/flutter 1439 (11.2%) 32 (15.0%) 1407 (11.1%) 0.072
Moderate to severe aortic stenosis 325 (2.5%) 12 (5.6%) 313 (2.5%) 0.004
Moderate to severe mitral stenosis 78 (0.6%) 3 (1.4%) 75 (0.6%) 0.139
Continued
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Hhistory of diabetes mellitus, history of myocardial infarction
within 6 weeks, symptomatic target lesion within 6 months,
contralateral carotid occlusion, and a history of New York
Heart Association Class III or IV heart failure within 6 weeks.
The patient characteristics most strongly associated with in-
hospital stroke or death in the ﬁnal model were a history of
recent myocardial infarction (odds ratio [OR] 2.66, 95% CI
1.89 to 3.74), the presence of a contralateral carotid stenosis
(OR 2.27, 95% CI 1.83 to 2.81), for a recent history of New
York Heart Association Class III or IV heart failure (OR 2.39,
95% CI 1.78 to 3.19). This model was found to have a
c-statistic of 0.65, demonstrating moderate discrimination.





Death No Stroke or Death P Value
Mechanical aortic or mitral valve 210 (1.6%) 5 (2.3%) 205 (1.6%) 0.402
Permanent pacemaker or ICD 657 (5.1%) 10 (4.7%) 647 (5.1%) 0.786
ASA physical classification grade <0.001
1 193 (1.5%) 1 (0.5%) 192 (1.5%)
2 1432 (11.2%) 17 (8.0%) 1415 (11.2%)
3 8660 (67.5%) 111 (52.4%) 8549 (67.8%)
4 2511 (19.6%) 81 (38.2%) 2430 (19.3%)
5 33 (0.3%) 2 (0.9%) 31 (0.2%)
Neurologic history and risk factors
Dementia or Alzheimer’s disease 307 (2.4%) 11 (5.2%) 296 (2.3%) 0.007
History of seizure or seizure disorder 261 (2.0%) 4 (1.9%) 257 (2.0%) 1.000
Previous carotid revascularization 1979 (15.4%) 34 (16.0%) 1945 (15.3%) 0.805
Prior CEA 1883 (14.6%) 31 (14.6%) 1852 (14.6%) 0.982
Prior CAS 122 (0.9%) 4 (1.9%) 118 (0.9%) 0.143
Prior ipsilateral CAS 20 (0.2%) 0 (0.0%) 20 (0.2%) 1.000
Prior ipsilateral CEA 240 (1.9%) 2 (0.9%) 238 (1.9%) 0.445
Neurologic event(s) preprocedure 5484 (42.6%) 116 (54.5%) 5368 (42.4%) <0.001
Prior TIA 3353 (26.0%) 67 (31.5%) 3286 (25.9%) 0.068
Prior ischemic stroke 1752 (13.6%) 43 (20.2%) 1709 (13.5%) 0.005
Prior hemorrhage or hemorrhagic stroke 78 (0.6%) 2 (0.9%) 76 (0.6%) 0.370
Procedure information
Target carotid vessel 0.507
Right 6523 (50.6%) 103 (48.4%) 6420 (50.6%)
Left 6366 (49.4%) 110 (51.6%) 6256 (49.4%)
Anesthesia type 0.058
General 11 671 (90.6%) 201 (94.4%) 11 470 (90.5%)
Local 1210 (9.4%) 12 (5.6%) 1198 (9.5%)
Urgent cardiac surgery within 30 d 431 (3.4%) 24 (11.5%) 407 (3.2%) <0.001
Target lesion symptomatic within 6 mo 4510 (35.0%) 101 (47.4%) 4409 (34.8%) <0.001
Restenosis in target vessel after prior CAS 228 (1.8%) 2 (0.9%) 226 (1.8%) 0.594
Restenosis in target vessel after prior CEA 228 (1.8%) 2 (0.9%) 226 (1.8%) 0.594
Contralateral carotid artery occlusion 686 (5.3%) 24 (11.3%) 662 (5.2%) <0.001
Fibromuscular dysplasia of carotid artery 21 (0.2%) 3 (1.4%) 18 (0.1%) 0.005
GFR indicate glomerular ﬁltration rate; LAD, left anterior descending coronary artery; LCx, left circumﬂex artery; RCA, right coronary artery; MI, myocardial infarction; CCS, Canadian
Cardiovascular Society; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ICD, implantable cardioverter deﬁbrillator; ASA, American Society of Anesthesiologists;
CEA, carotid endarterectomy; CAS, carotid artery stenting; TIA, transient ischemic attack.
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Based on the multivariable model, an integer-based scoring
system (the NCDR CEA score) was built for clinical use
(Table 3). Observed rates of death or stroke are shown as a
function of the point total on the integer scoring system
(Figure 2).
Risk-Standardized Event Rates by Hospital
Using the multivariable model, standardized ratios of in-
hospital stroke or death for each hospital were generated by
hospital and were plotted in Figure 3. These ratios varied from
0.64 to 2.10, suggesting differences in CEA outcomes among
the registry hospitals not attributable to observable differ-
ences in case mix.
Discussion
Using a large population of patients undergoing CEA in the
United States, we developed and validated a risk model and a
risk score that predicts in-hospital stroke and death after CEA.
The risk factors we identiﬁed have been previously described
by other investigators to increase risk of adverse events after
CEA, either alone or in combination with other factors.
22,23
Hospital Quality Assessment
With growing emphasis on public outcome reporting, we
believe that risk models based on easily collected clinical
Table 2. Multivariable Predictors of In-Hospital Stroke or Death, N=12 889
b-Coefﬁcient SE t Value P Value Odds Ratio (95% CI)
Intercept 6.1609 0.5974 10.31 <0.0001
Age (per 10 y) 0.2321 0.07026 3.30 0.0010 1.26 (1.18 to 1.35)
Peripheral artery disease 0.3353 0.1386 2.42 0.0156 1.40 (1.22 to 1.61)
Diabetes mellitus 0.3167 0.1349 2.35 0.0189 1.37 (1.20 to 1.57)
MI within 6 weeks 0.9788 0.3408 2.87 0.0041 2.66 (1.89 to 3.74)
Target lesion symptomatic in prior 6 months 0.5374 0.1354 3.97 <0.0001 1.71 (1.49 to 1.96)
Contralateral carotid occlusion 0.8177 0.2143 3.82 0.0001 2.27 (1.83 to 2.81)
NYHA Class III/IV 0.8694 0.2918 2.98 0.0029 2.39 (1.78 to 3.19)
MI, myocardial infarction; NYHA, New York Heart Association.
Figure 1. Observed vs predicted probability of in-hospital
stroke or death. This calibration plot depicts observed (y-
axis) vs predicted (x-axis) in-hospital stroke or death rates
for patients undergoing carotid endarterectomy. Differ-
ences between observed and predicted event rates were
small across all levels of risk (Hosmer-Lemeshow P=0.52).




50 to 59 2
60 to 69 4
70 to 79 6
80 to 89 8
≥90 10
Peripheral artery disease 3
Diabetes mellitus 3
MI within 6 weeks 8
Target lesion symptomatic in previous 6 months 5
Contralateral carotid occlusion 7
NYHA Class III/IV 7
NCDR indicates National Cardiovascular Data Registry; CEA, carotid endarterectomy;
MI, myocardial infarction; NYHA, New York Heart Association.
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Hfactors will have an increasingly important place in the
assessment and reporting of health care quality. The NCDR
CEA Risk Score includes relevant clinical factors that are likely
not available through traditional administrative data sets.
Inclusion of these clinical factors in the risk model improves
the face validity of these tools for clinicians and underscores
the importance of clinical registries in measuring hospital
quality. The variability in standardized adverse event ratios
observed across participating hospitals provides evidence
that such models may be useful to hospitals in efforts to
benchmark performance against other hospitals and for
lower-performing hospitals to initiate efforts to improve
outcomes.
NCDR CEA Risk Score in the Context of Previous
Risk Stratiﬁcation Models
This risk score was developed in a large data set (>10 000
procedures) of CEA in both symptomatic and asymptomatic
patients from a broad range of hospitals across the United
States. The patient population was not limited to Medicare
beneﬁciaries or those enrolled in clinical trials. We also note
the overall low event rates in this population of patients.
This could indicate evolution of treatment of this patient
population (including improved background medical therapy,
surgical techniques, anesthesia care, etc); it could be related
to patient selection in the data set; or it could be related
to the self-reported nature of the data without routine,
independent neurologist assessment in every patient.
Changes in surgical and perioperative practice, indicated
by changing rates of adverse events over time, underscore
the need for ongoing surveillance and, when necessary,
updating risk prediction algorithms that are intended for
clinical practice. Importantly, this risk score was developed
accounting for natural clustering in the data by hospital site
and can be used for assessments of hospital quality at the
site level.
Study Limitations
Several limitations warrant discussion. First, prediction of in-
hospital stroke or death is limited to the in-hospital period and
does not predict long-term outcomes in these patients as this
information is not available in CARE. Second, we did not
adjust for all variables that inﬂuence CEA-related risk, as
indicated by the moderate discriminative ability of the model.
For instance, the stenosis severity of the carotid lesion and
the overall level of disability of the patient before the index
procedure are not well characterized in CARE and thus have
not been captured in the model. However, models with
imperfect patient-level discrimination are still useful for the
assessment of hospital quality without introducing bias so
long as unobserved variables strongly associated with in-
hospital stroke or death are similarly prevalent across
participating hospitals.
20 The stroke end point was not
adjudicated beyond reporting by individual sites and patients
were not routinely tested by a neurologist in a standardized
way postprocedure. The CARE Registry thus could underre-
port minor strokes, as has occurred in other studies.
However, the overall rates of death and stroke in our study
at 30 days were similar to those observed in both the
Figure 2. Stroke or death rates based on cumulative risk score.
Observed stroke or death rates are shown as a function of the
total number of points on the NCDR CEA risk score. CEA indicates
carotid endarterectomy; MACE, combined endpoint of stroke or
death; NCDR, National Cardiovascular Data Registry.
Figure 3. Histogram of hospitals according to risk-standardized
event rates. Risk standardized stroke/death rates indicate in-
hospital stroke or death.
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HCREST (Carotid Revascularization Endarterectomy versus
Stenting Trial) trial and other quality improvement pro-
grams.
12,24 Finally, this registry was not designed to
inform us about patients who were screened but did not
have CEA.
Conclusions
We developed and internally validated a risk model to
predict in-hospital stroke or death after CEA using data from
the CARE Registry. The model will be used to support
hospital comparisons of risk-adjusted outcomes among the
>100 participating hospitals, allowing for accurate bench-
marking of hospital performance or quality improvement
efforts for CEA. In addition, it may provide valuable
information about procedural risk for patients considering
this therapy.
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